WO2010080757A3 - Combinations with an alpha-4beta-2 nicotinic agonist - Google Patents
Combinations with an alpha-4beta-2 nicotinic agonist Download PDFInfo
- Publication number
- WO2010080757A3 WO2010080757A3 PCT/US2010/020118 US2010020118W WO2010080757A3 WO 2010080757 A3 WO2010080757 A3 WO 2010080757A3 US 2010020118 W US2010020118 W US 2010020118W WO 2010080757 A3 WO2010080757 A3 WO 2010080757A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- combination
- nicotinic agonist
- 4beta
- alpha
- combinations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Abstract
The present invention related to a combination of (a) a α4β2 nicotinic agonist and (b) a Second Therapeutic Agent, as defined under group A or group B. The invention further relates to pharmaceutical compositions comprising said combination and to methods of treating CNS disorders in mammals by administrating said combination. The invention further relates to a kit comprising the combination and use of said kits in treatment of CNS disorders, such as cognitive dysfunction in schizophrenia, dementia and/or Alzheimer's disease or those disorders defined below.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14295909P | 2009-01-07 | 2009-01-07 | |
US61/142,959 | 2009-01-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010080757A2 WO2010080757A2 (en) | 2010-07-15 |
WO2010080757A3 true WO2010080757A3 (en) | 2010-12-23 |
Family
ID=42035948
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/020118 WO2010080757A2 (en) | 2009-01-07 | 2010-01-05 | Combinations with an alpha-4beta-2 nicotinic agonist |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2010080757A2 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9108948B2 (en) | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
SG173312A1 (en) | 2006-06-23 | 2011-08-29 | Abbott Lab | Cyclopropyl amine derivatives as histamin h3 receptor modulators |
US9186353B2 (en) | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
WO2012037258A1 (en) | 2010-09-16 | 2012-03-22 | Abbott Laboratories | Processes for preparing 1,2-substituted cyclopropyl derivatives |
BR112019010466A2 (en) | 2016-12-20 | 2019-09-10 | Lts Lohmann Therapie Systeme Ag | asenapine-containing transdermal therapeutic system |
US11337932B2 (en) | 2016-12-20 | 2022-05-24 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene |
US11033512B2 (en) | 2017-06-26 | 2021-06-15 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer |
CA3101420A1 (en) | 2018-06-20 | 2019-12-26 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000075110A1 (en) * | 1999-06-07 | 2000-12-14 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
WO2006114400A1 (en) * | 2005-04-26 | 2006-11-02 | Neurosearch A/S | Novel oxadiazole derivatives and their medical use |
WO2007134034A1 (en) * | 2006-05-09 | 2007-11-22 | Targacept, Inc. | Polymorph forms of (2s) - (4e) -n-methyl-5- (3-isopropoxypyridin) yl] -4-penten-2-amine for the treatment of central nervous system disorders |
WO2007134038A2 (en) * | 2006-05-09 | 2007-11-22 | Astrazeneca Ab | Salt forms of (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine |
WO2008034041A2 (en) * | 2006-09-15 | 2008-03-20 | Astrazeneca Ab | Therapeutic combinations |
WO2008073942A2 (en) * | 2006-12-12 | 2008-06-19 | Abbott Laboratories | Pharmaceutical compositions and their methods of use |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL107184A (en) | 1992-10-09 | 1997-08-14 | Abbott Lab | Heterocyclic ether compounds that enhance cognitive function |
US5604231A (en) | 1995-01-06 | 1997-02-18 | Smith; Carr J. | Pharmaceutical compositions for prevention and treatment of ulcerative colitis |
US5597919A (en) | 1995-01-06 | 1997-01-28 | Dull; Gary M. | Pyrimidinyl or Pyridinyl alkenyl amine compounds |
US5585388A (en) | 1995-04-07 | 1996-12-17 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
US5583140A (en) | 1995-05-17 | 1996-12-10 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of central nervous system disorders |
US20020052497A1 (en) | 2000-03-09 | 2002-05-02 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
WO1997040011A1 (en) | 1996-04-23 | 1997-10-30 | R. J. Reynolds Tobacco Company | Pharmaceutical compositions for prevention and treatment of central nervous system disorders |
US7098331B2 (en) | 2003-03-05 | 2006-08-29 | Targacept, Inc. | Arylvinylazacycloalkane compounds and methods of preparation and use thereof |
TWI405763B (en) | 2006-11-02 | 2013-08-21 | Targacept Inc | Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloalkanes |
TW200845977A (en) | 2007-03-30 | 2008-12-01 | Targacept Inc | Sub-type selective azabicycloalkane derivatives |
-
2010
- 2010-01-05 WO PCT/US2010/020118 patent/WO2010080757A2/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000075110A1 (en) * | 1999-06-07 | 2000-12-14 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
WO2006114400A1 (en) * | 2005-04-26 | 2006-11-02 | Neurosearch A/S | Novel oxadiazole derivatives and their medical use |
WO2007134034A1 (en) * | 2006-05-09 | 2007-11-22 | Targacept, Inc. | Polymorph forms of (2s) - (4e) -n-methyl-5- (3-isopropoxypyridin) yl] -4-penten-2-amine for the treatment of central nervous system disorders |
WO2007134038A2 (en) * | 2006-05-09 | 2007-11-22 | Astrazeneca Ab | Salt forms of (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine |
WO2008034041A2 (en) * | 2006-09-15 | 2008-03-20 | Astrazeneca Ab | Therapeutic combinations |
WO2008073942A2 (en) * | 2006-12-12 | 2008-06-19 | Abbott Laboratories | Pharmaceutical compositions and their methods of use |
Non-Patent Citations (1)
Title |
---|
LETCHWORTH S R ET AL: "An orally active neuronal nicotinic receptor modulator with", ABSTRACTS OF THE ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE; 33RD ANNUAL MEETING OF THE SOCIETY OF NEUROSCIENCE; NEW ORLEANS, LA, USA; NOVEMBER 08-12, 2003, SOCIETY FOR NEUROSCIENCE, WASHINGTON, DC, US, vol. 2003, 1 January 2003 (2003-01-01), pages 1, XP008125807, ISSN: 0190-5295 * |
Also Published As
Publication number | Publication date |
---|---|
WO2010080757A2 (en) | 2010-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010080757A3 (en) | Combinations with an alpha-4beta-2 nicotinic agonist | |
WO2007092329A3 (en) | Pharmaceutical compositions for treating depression, anxiety and neurodegenerative disorders | |
IL193080A0 (en) | Methods, compositions, and kits for the treatment of musculoskeletal disorders and symptoms associated therewith | |
TN2018000322A1 (en) | Allosteric modulators of nicotinic acetylcholine receptors | |
WO2009127642A3 (en) | Use of lrrk2 inhibitors for neurodegenerative diseases | |
WO2007127505A3 (en) | Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system | |
WO2010030813A3 (en) | Methods for inhibiting ocular angiogenesis | |
WO2009036175A3 (en) | F1f0-atpase inhibitors and related methods | |
MX2009008531A (en) | Nitrogen-containing heterocyclyl ketones and methods of use. | |
WO2010127099A3 (en) | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same | |
WO2007058602A3 (en) | Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer’s disease, neurodegeneration and dementia. | |
MX2010002312A (en) | Triazolopyridine compounds and their use as ask inhibitors. | |
WO2006058868A8 (en) | Substituted pteridines for treating inflammatory diseases | |
WO2010006130A3 (en) | Pde-10 inhibitors | |
IL208673A (en) | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands | |
GB2463833A (en) | Methods and compositions for the treatment of neurological disorders | |
WO2012080729A3 (en) | Casein kinase 1delta (ck1delta) inhibitors and their use in the treatment of neurodegenerative diseases such as tauopathies | |
WO2006121560A8 (en) | Methods and compositions for treatment of cns disorders | |
WO2009158467A3 (en) | Di-substituted phenyl compounds as phosphodiesterase 10 inhibitors | |
CL2010000129A1 (en) | Compounds derived from substituted fused benzazepines, acetylcholine receptor modulators; pharmaceutical composition; preparation procedure; and its use in the treatment of CNS disorders such as schizophrenia, dementia, Alzheimer's disease, multiple sclerosis, among others. | |
EP1910321A4 (en) | New compounds, process for their preparation, intermediates, pharmaceutical compositions and their use in the treatment of 5-ht6 mediated disorders such as alzheimer's disease, cognitive disorders, cognitive impairment associated with schizophrenia, obesity and parkinson's disease | |
MX357383B (en) | 5-(3-aminophenyl)-5-alkyl-5,6-dihydro-2h-[1,4]oxazin-3-amine derivatives. | |
UA92636C2 (en) | Tetrahydro-pyrimidoazepines as modulators of trpv1 | |
WO2009105585A3 (en) | Postsynaptically targeted chemodenervation agents and their methods of use | |
WO2008129023A3 (en) | Oligonucleotide compositions for the treatment of alzheimer's disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10700135 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10700135 Country of ref document: EP Kind code of ref document: A2 |